AzTrials
AzTrials

Peripheral Nerve Injury Upper LimbPhase 3NCT06616025

This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.

A Phase 3 study testing NTX-001 (PEG-Fusion) in people with Peripheral Nerve Injury Upper Limb and Peripheral Nerve Injury (PNI), run by Neuraptive Therapeutics Inc. at 25 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
NTX-001 (PEG-Fusion)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
98 participants
Where
25 sitesUnited States
Study dates
10 Feb 2025to 30 Apr 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The subject has voluntarily agreed to participate in this study and has signed an Institutional Review Board (IRB) approved informed consent form.
  • The subject is between eighteen (18) and eighty (80) years of age.
  • The subject has clinical evidence of a Sunderland's 4th degree (Class II) or 5th degree (Class III) nerve transection(s) that has resulted in upper extremity nerve impairment that requires surgical treatment.

Who cannot join

  • Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
  • Subjects requiring nerve repair involving an autograft, allograft or conduit(s).
  • Subjects with multiple transected nerve injuries are allowed into the study only if all injuries are amenable to direct repair.
  • Subjects who, in the judgement of the investigator, are not likely to demonstrate meaningful recovery within a reasonable time frame during follow up due to significant muscle atrophy or other morbidity.
  • The subject's injury is a result of a suicide attempt or self- harm.
  • The subject has documented history or clinical signs of any condition where NTX-001 might not prove beneficial (e.g., systemic neuromuscular disease, systemic neurological deficit, or other treatments known to affect the growth and/or physiology of the neural and vascular system).
Show all 9Show fewer
  • The subject has a known allergy to polyethylene glycol (PEG) or human grade silicone.
  • The subject is pregnant or breastfeeding.
  • The subject is currently enrolled in another investigational study or has participated in an investigational study within 30 days prior to screening.

Trial locations and contacts

25 sites in 1 country. Contact the study team or a site near you to ask about taking part.

25 sites in 1 country

United States25 sites, 25 recruiting
  • Grady Health

    Atlanta, Georgia, 30303

    Nicole A Zelenski, MD, 404-251-1566, nicole.ann.zelenski@emory.edu

    Morgan Fuller, MS, 404-251-8953, mrfulle@emory.edu

    Recruiting
  • Curtis National Center at MedStar Union Memorial Hospital

    Baltimore, Maryland, 21218

    Kenneth R Means Jr., MD, 410-554-2486, kennethrmeans@curtishand.com

    Ike Fleming, Research Program Manager, 410-554-2486, Ike.C.Fleming@medstar.net

    Recruiting
  • The Cooper Health System

    Camden, New Jersey, 08103

    David A Fuller, MD, 856-968-7262, Fuller-David@CooperHealth.edu

    Pietro M Gentile, Manager of Research Division, 856-213-0094, gentile-pietro@CooperHealth.edu

    Recruiting
  • Medical University of South Carolina

    Charleston, South Carolina, 29429

    Charles A Daly, MD, 843-876-2211, dalyc@musc.edu

    Lisa Mock, 843-876-2211, mockl@musc.edu

    Recruiting
  • UVA Health

    Charlottesville, Virginia, 22903

    Brett DeGeorge, MD, 434-924-5078, bd6u@virginia.edu

    Milos Lesevic, MD, 434-924-2549, ML4EC@uvahealth.org

    Recruiting
  • University of Chicago

    Chicago, Illinois, 60637

    Jeffrey Stepan, MD MSc, 773-702-0494, jstepan@bsd.uchicago.edu

    Michael Koch, 773-834-0822, mkoch@bsd.uchicago.edu

    Recruiting
  • UC Health

    Cincinnati, Ohio, 45267

    Sonu Jain, MD, FACS, 513-558-2765, sonu.jain@uc.edu

    Brittany Rowley, CCRC Clinical Research Professional III, 513-558-2765, rowleybm@ucmail.uc.edu

    Recruiting
  • University of Cincinnati Health

    Cincinnati, Ohio, 45267

    Sonu Jain, MD, 504-296-8215, jain3su@ucmail.uc.edu

    Brittany Rowley, Lead Coordinator, 513-558-2765, rowleybm@ucmail.uc.edu

    Recruiting
  • The MetroHealth System

    Cleveland, Ohio, 44109

    Kyle J Chepla, MD, 216-778-7878, kchepla@metrohealth.org

    Hannah Amiott, Clinical Research Coordinator, 216-778-1163, HAmiott@metrohealth.org

    Recruiting
  • Missouri Orthopaedic Institute

    Columbia, Missouri, 65211

    Julia Nuelle, MD, 573-882-2663, julia.nuelle@health.missouri.edu

    Bryce Fletcher, 573-884-1248, brycefletcher@health.missouri.edu

    Recruiting
  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43212

    Ryan Schmucker, MD, 614-293-8566, Ryan.Schmucker@osumc.edu

    Emily Rice, 614-293-5871, Emily.Rice2@osumc.edu

    Recruiting
  • Baylor, Scott and White Health

    Dallas, Texas, 75246

    Asadullah Helal, MD, 469-800-7200, Asadullah.Helal@BSWHealth.org

    Angela Young Young - Clinical Research Coordinator, 214-820-4787, Angela.Young1@BSWHealth.org

    Recruiting
  • Cedars Sinai Medical Center

    Los Angeles, California, 90048

    Meghan C McCullough, MD, 703-371-9220, Meghan.McCullough@cshs.org

    Michael Fernandez, Clinical Research Coordinator, 310-423-0201, Michael.Fernandez2@cshs.org

    Not yet recruiting
  • University of Louisville

    Louisville, Kentucky, 40202

    Tuna Ozyurekoglu, MD, 502-562-0352, tuna.ozyurekoglu@louisville.edu

    Anne Jerde, Lead Coordinator, 502-852-5251, ann.jerde@louisville.edu

    Recruiting
  • Texas Tech

    Lubbock, Texas, 79415

    Brendan J MacKay, MD, 806-743-2584, brendan.j.mackay@ttuhsc.edu

    Evan J Hernandez, Clinical Researcher - MBA, 806-743-6846, evan.j.hernandez@ttuhsc.edu

    Recruiting
  • Louisiana State University Health Sciences Center

    New Orleans, Louisiana, 70112

    Harvey Chim,, MD, (504) 568-4750, hchim@lsuhsc.edu

    Tanja Milosavljevic, MSc, PhD, 504-568-6876, tmilos@lsuhsc.edu

    Recruiting
  • NYU Langone Health

    New York, New York, 10003

    Jacques Hacquebord, MD, 212-263-7582, Jacques.hacquebord@nyulangone.org

    Anne Genzelev, 212-263-7582, Anne.Genzelev@nyulangone.org

    Recruiting
  • Rothman Orthopedics - Advent Health

    Orlando, Florida, 32804

    Amir Reza Kachooei, MD PhD, 844-407-4070, amir.kachooei@rothmanortho.com

    Rosemary Vargas, Coordinator, 407-752-5452, Rosemary.Vargas@AdventHealth.com

    Recruiting
  • Orlando Health Orlando Regional Medical Center

    Orlando, Florida, 32806

    Justin Zumsteg, MD, 321-843-5851, Justin.Zumsteg@orlandohealth.com

    Carlis Rodriguez-Saavedra, 321-841-3631, Carlis.RodriguezSaavedra@orlandohealth.com

    Recruiting
  • University of Pennsylvania, Department of Orthopaedic Surgery

    Philadelphia, Pennsylvania, 19104

    Ines C Lin, MD, 215-662-7300, ines.lin@uphs.upenn.edu

    Annamarie D. Horan, MPA, PhD, 215-847-0132, horana@pennmedicine.upenn.edu

    Recruiting
  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15212

    Steven Regal, MD, 877-660-6777, Steven.REGAL@ahn.org

    Mary Fetter - Lead Clinical Research Coordinator, 412-359-8292, Mary.Fetter@ahn.org

    Recruiting
  • University of Utah Health

    Salt Lake City, Utah, 84132

    Mark A Mahan, MD, FAANS, 801-585-7917, mark.mahan@hsc.utah.edu

    Kirstianna Lombardi, Lead Coordinator, 801-585-9821, kirstianna.lombardi@utah.edu

    Recruiting
  • UCSF Health

    San Francisco, California, 94158

    Nicolas H Lee, MD MS, 415-206-8765, nicolas.lee@ucsf.edu

    Tigist Belaye, MPA, CCRP, 415-205-5375, Tigist.Belaye@ucsf.edu

    Not yet recruiting
  • Harborview Medical Center

    Seattle, Washington, 98104

    Yusha ( Katie) Liu, MD PhD, 206-744-3000, HMCnerve@uw.edu

    Laura Hennessy, RN, 206-744-7723, hennessy@uw.edu

    Recruiting
  • Barnes-Jewish Hospital 1 Barnes Jewish Hospital Plaza St.

    St Louis, Missouri, 63110

    David M Brogan, MD, MSc, 314-747-2813, brogand@wustl.edu

    Michelle Moore, Clinical Research Coordinator, 314-273-2403, michellemoore@wustl.edu

    Recruiting

Other trials in United States

About this study

Official title: Phase 3, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care (Neurorrhaphy) in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair.

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80.

Read the detailed description

NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.

Being tested
NTX-001 (PEG-Fusion)
Keywords
Transected Nerves, Requiring Surgical Repair, Upper Extremity
Medical subject headings
Peripheral Nerve Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NTX-001 (PEG-Fusion)Combination product

    One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.

Study groups in NCT06616025
Study groupRoleWhat they receive
NTX-001ExperimentalNTX-001 used during the surgical repair of an upper extremity peripheral nerve injury in conjunction with standard suture neurorrhaphy.
Receives: Combination Product: NTX-001 (PEG-Fusion)
Standard Suture NeurorrhaphyNo interventionStandard of Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain)

    The subject will complete the MHQ questionnaire at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48. A measure of the mean of MHQ in the Two Domains, Activities of Daily Living and Pain Scores, at Week 24 in the NTX-001 group as compared to Standard of Care (SoC). In the ADL subdomain, a higher component score indicates better function. In the Pain subdomain, a higher component score indicates greater pain. A total MHQ score of 100 is considered the best functional score.

    Measured: Screening Visit, Week 24

  2. Safety - Columbia-Suicide Severity Rating Scale

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a suicide risk assessment tool. The C-SSRS tool asks; whether and when the subject has had a thought about suicide (ideation); what actions they might have taken and what they did to prepare for suicide; whether and when they attempted suicide or began a suicide attempt that was either interrupted by another person or stopped of their own volition. The answers identify whether someone is at risk for suicide, assessing the severity and immediacy of that risk, and gauging the level of support that the person needs. The first assessment is done by study staff at screening. Subsequent assessments will be completed by the subject at Weeks 4, 12, and 48. A score of 0 indicates no risk, 1-2 indicates low risk, and 3+ indicates moderate to high risk.

    Measured: Screening Visit, Weeks 4, 12, and 48

Secondary outcomes (13)
  1. Intraoperative CheckPoint® Stimulation.

    A CheckPoint® Stimulator will be used intra-operatively to detect immediate reconnection of severed peripheral nerves (axons) in mixed-motor nerves only. The measures include in response of direct nerve stimulation, proximally and distally to suture site.

    Measured: In Operating Room

  2. MHQ Total Score

    The MHQ quantifies different impairments between the subjects in uninjured and involved upper extremities. A general survey of hand function includes twenty-five items for the right and the left hand, as well as questions for both hands. Questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

    Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48

  3. Time to Return to Function

    Achievement of seventy-five (75)% function in the combined ADL and pain MHQ domain scores. The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

    Measured: Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

  4. Change in NPRS

    The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.

    Measured: Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48

  5. Semmes Weinstein Monofilament Test (SWMT)

    SWMT provides information on protective sensation, the rigorous system can detect relatively minor differences in sensory function, and changes will occur early in nerve injury. The assessment tool consists of a set of monofilaments that vary in thickness and diameter, the gradient forces of these monofilaments that subjects\' can feel, range from 0.086 gm to 0.448gm. The normal value in the hand is in the range of the green filament (1.65 to 2.83 mN).

    Measured: Weeks 2, 4, 8, 12, 24, 36, 48.

  6. MHQ Two Domain Score

    The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.

    Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48

  7. Change from Week 2 in MHQ Two Domain Score

    The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.

    Measured: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

  8. Medical Research Council Classification (MRCC) Sensory Score

    The scale is commonly used including 2 Point Discrimination for grading the sensory outcome after peripheral nerve surgery. This scale is categorized into S0-S4: S0 is the absence of sensibility; S1 is the recovery of deep cutaneous pain; S2 is the return of superficial cutaneous pain and some degree of tactile sensibility; S3 is the return of superficial cutaneous pain and tactile sensibility without over response; and S4 is the complete recovery.

    Measured: Weeks 2, 4, 8, 12, 24, 36, and 48.

  9. Medical Research Council Classification (MRCC) Motor Score

    This assessment is conducted on mixed motor nerve injuries only. Strength can best be assessed by isolating an individual muscle group and comparing power with that of the subject. It can be conducted to assess larger muscles or muscle groups as well as intrinsic muscles of the hand. Measuring the difference between the affected limb and the contralateral limb. 0/5 is no muscle activation whatsoever; 1/5 is muscle activation without limb movement; 2/5 implies that the limb can be moved only when gravity is taken out of the equation; 3/5 means that the subject can overcome gravity but not resistance;• 4/5 (or 4+ or 4-) implies weakness with enough strength to overcome varying degrees of physical resistance; 5/5 is full strength.

    Measured: Weeks 2, 4, 8, 12, 24, 36, 48

  10. Change from Baseline (W2) in Numeric Pain Rating Scale (NPRS)

    The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.

    Measured: Weeks 2, 24.

  11. Patient Global Impression of Change Score

    This scale evaluates all aspects of patients; health and assesses if there has been an improvement or decline in clinical status. PGIC is a 7-point scale depicting a subjects rating of overall improvement. The subject rates their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."

    Measured: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48

  12. Change in Total MHQ Score

    The MHQ quantifies different impairments between the subjects uninjured and involved upper extremities. It was designed as a general survey of hand function and includes twenty-five items for the right and the left hand, as well as questions for both hands. Furthermore, questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

    Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

  13. Change from Baseline in Patient Global Impression of Severity Score (PGIS)

    The PGIS is a single question asking the subject to rate the severity of the injury from the last visit. PGIS is a scale depicting a subject's rating of overall severity. The subject scores their perception of severity as "none," "mild," "moderate," "severe," or "very severe."

    Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Sep 2024
  2. Study start10 Feb 2025
  3. Primary completion31 Mar 2027 (estimated)
  4. Study completion30 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Treatment vs. Standard of Care
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
98 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06616025
Sponsor's protocol ID
NTx24301
Status last verified
May 2026
First submitted
24 Sep 2024
Last updated
6 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing NTX-001 (PEG-Fusion) in people with Peripheral Nerve Injury Upper Limb and Peripheral Nerve Injury (PNI), run by Neuraptive Therapeutics Inc. at 25 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 25 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Seth Schulman, MD (215-206-9504, seth.schulman@neuraptive.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain) (time frame: Screening Visit, Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in